Structure Therapeutics reported Phase 2 data showing its oral GLP-1 candidate aleniglipron achieved up to 16% placebo‑adjusted weight loss at 44 weeks, positioning the pill as a potential oral competitor to injectable GLP‑1s. The company said a staged dosing regimen improved tolerability and limited discontinuations in the trial. Investigators randomized patients across stepped doses and measured sustained weight loss at 44 weeks; analysts described the results as best‑in‑class for oral GLP‑1s. Structure plans to advance aleniglipron into Phase 3 while monitoring a crowded field that now includes Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron. The readout intensifies competition in obesity therapeutics and raises commercial and manufacturing questions for oral GLP‑1 supply, pricing and positioning versus injectables. Drug developers should expect accelerated regulatory and commercial planning as multiple oral candidates progress toward pivotal trials.